Published online October 18, 2004
PEDIATRICS Vol. 114 No. 5 November 2004, pp. e634-e641 (doi:10.1542/peds.2003-0264-F)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shea, S.
Right arrow Articles by Dunbar, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shea, S.
Right arrow Articles by Dunbar, F.
Related Collections
Right arrow Therapeutics & Toxicology

ELECTRONIC ARTICLE

Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders

Sarah Shea, MD*, Atilla Turgay, MD{ddagger}, Alan Carroll, MD§, Miklos Schulz, PhD||, Herbert Orlik, MD*, Isabel Smith, PhD* and Fiona Dunbar, MBBCh

* IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
{ddagger} University of Toronto, Toronto, Ontario, Canada
§ Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada
|| SciAn Clinical, Etobicoke, Ontario, Canada
Janssen-Ortho Inc, Toronto, Ontario, Canada

Objective. To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD).

Methods. In this 8-week, randomized, double-blind, placebo-controlled trial, risperidone/placebo solution (0.01–0.06 mg/kg/day) was administered to 79 children who were aged 5 to 12 years and had PDD. Behavioral symptoms were assessed using the Aberrant Behavior Checklist (ABC), Nisonger Child Behavior Rating Form, and Clinical Global Impression-Change. Safety assessments included vital signs, electrocardiogram, extrapyramidal symptoms, adverse events, and laboratory tests.

Results. Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo. By study endpoint, risperidone-treated subjects exhibited a 64% improvement over baseline in the irritability score almost double that of placebo-treated subjects (31%). Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the ABC; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom. More risperidone-treated subjects (87%) showed global improvement in their condition compared with the placebo group (40%). Somnolence, the most frequently reported adverse event, was noted in 72.5% versus 7.7% of subjects (risperidone vs placebo) and seemed manageable with dose/dose-schedule modification. Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure. Extrapyramidal symptoms scores were comparable between groups.

Conclusions. Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children.

Key Words: autistic disorder • pervasive developmental disorders • risperidone

Abbreviations: PDD, pervasive developmental disorders • EPS, extrapyramidal symptom • CARS, Childhood Autism Rating Scale • ESRS, Extrapyramidal Symptom Rating Scale • ABC, Aberrant Behavior Checklist • N-CBRF, Nisonger Child Behavior Rating Form • VAS, Visual Analog Scale • CGI-C, Clinical Global Impression-Change • ITT, intention-to-treat • RUPP, Research Units on Pediatric Psychopharmacology

Accepted Apr 29, 2004.




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
O. Sabuncuoglu
Risperidone-to-methylphenidate switch reaction in children: three cases
J Psychopharmacol, March 1, 2007; 21(2): 216 - 219.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry, June 1, 2006; 63(6): 679 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
R. P Malone
Discontinuing risperidone results in relapse in children with autism spectrum disorders.
Evid. Based Ment. Health, May 1, 2006; 9(2): 56 - 56.
[Full Text] [PDF]

Home page
 AAP NewsHome page
C. Kemp
Risperidone effectively treats disruptive behavior
AAP News, December 1, 2004; 25(6): 280 - 280.
[Full Text] [PDF]